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Abstract
Background: HIV/AIDS and depression are projected to be the two leading causes of disability by 2030. HIV/AIDS and
anxiety/depression are interlinked. People suffering from depression may be more likely to engage in risky sexual
behaviour, and therefore at greater risk of contracting HIV. An HIV + diagnosis may trigger symptoms of anxiety and
depression, which may in turn result in risky sexual behaviour and the spread of HIV. This study explores correlates of
anxiety and depression in patients enrolled in a public sector ART programme in South Africa.
Methods: Interviews were conducted with 716 patients initiating ART at twelve public health care facilities in the
Free State. Symptoms of anxiety and depression were measured using the Hospital Anxiety and Depression Scale
(HADS). An 8+ cut-off was used to identify possible cases of anxiety and depression. Multivariate logistic regression
analysis, using STATA Version 11, was performed to identify correlates of anxiety and depression.
Results: The prevalence of symptoms of respectively anxiety and depression amongst this study population in the
Free State was 30.6% and 25.4%. The multivariate logistic regression analyses identified five correlates of symptoms
of anxiety and depression. Disruptive side effects (OR = 3.62, CI 1.95-6.74) and avoidant coping (OR = 1.42, CI 1.22-
1.65) were associated with a greater number of symptoms of anxiety. Stigma was associated with an increase in
symptoms of anxiety (OR = 1.14, CI 1.07-1.21) and of depression (OR = 1.13, CI 1.06-1.20), while being a widow (OR
= 0.30, CI 0.13-0.69) and participating in a support group (OR = 0.21, CI 0.05-0.99) were associated with decreased
symptoms of depression.
Conclusions: The findings from the study provide valuable insights into the psychosocial aspects of the Free State
public-sector ART programme. Combined with the literature on the intricate link between mental health problems
and treatment outcomes our results emphasise firstly, the necessity that resources be allocated for both screening
and treating mental health problems and, secondly, the need for interventions that will encourage support-group
participation, address ART side effects, reduce maladaptive coping styles, and minimise the stigma associated with
symptoms of anxiety and/or depression.
Background
HIV/AIDS and depression are projected to be the
world’s two leading causes of disability by 2030 [1].
Worldwide, 33 million people are currently living with
HIV. In 2009, there were an estimated 2.6 million new
HIV infections and 1.8 million deaths due to AIDS [2].
Depression, on the other hand, affects 121 million peo-
ple globally [3].
Importantly, HIV/AIDS and anxiety/depression are
interlinked. People suffering from depression may be
more likely to engage in risky sexual behaviour, and
they are therefore at greater risk of contracting HIV
[4-6]. Conversely, an HIV + diagnosis may trigger symp-
toms of anxiety and depression [7,8], which could once
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any medium, provided the original work is properly cited.again lead to risky sexual behaviour and the spreading of
the virus. In addition, studies have shown that people
suffering from depression are less likely to adhere to
treatment - treatment for both mental illness and for
antiretroviral treatment (ART) [9]. Depression may
therefore lead to non-adherence to ART and result in
poorer health. Unfortunately, more than half of the HIV
+ population that suffer from depression have not
received an official diagnosis of their depression [10].
Recent studies on the prevalence of anxiety and
depression in HIV/AIDS patients who are on ART in
resource-limited settings confirm this link. Symptoms of
anxiety and depression among 386 people initiating
ART in Brazil were measured using the Hospital, Anxi-
ety and Depression Scale (HADS) (≤ 10). The prevalence
of anxiety and depression, respectively, was 35.8% and
21.8% [11]. A study in Uganda assessed the prevalence
of symptoms of depression in 1017 patients eligible for
A R Tu s i n gt h eC e n t r ef o rE p i d e m i o l o g i cS t u d i e s
Depression Scale (≥ 23). The prevalence of depression
was 47% [12].
A study in Cape Town, South Africa, assessed the pre-
valence of psychiatric disorders using the Mini Interna-
tional Neuropsychiatric Interview among 149 recently
diagnosed HIV/AIDS patients. The prevalence of anxiety
was 6.7% and that of depression was 34.9% [13,14],
which highlights the extent of anxiety and/or depression
in HIV + populations. Prevalence rates must however be
interpreted with caution as location of study, study
population and different types of measures make it
impossible to arrive at a single prevalence rate for anxi-
ety or depression. In addition, self-reported measures
and psychiatric screening tools- such as HADS- report
higher rates of depression than do diagnostic evaluations
[15].
Researchers have identified a broad spectrum of pro-
tective and risk factors associated with anxiety and
depression in HIV + populations. Apart from sociode-
mographic characteristics, such as age and gender, cor-
relates include socio-economic (education, income,
poverty), behavioural (alcohol use, sexual activity), psy-
chosocial (disclosure, family support, prior depression,
family history of depression, positive coping, stigma, and
social support) and health-related factors (pain, health
status, time on treatment) [11,13,16-28].
The complex interrelationship between these protec-
tive and risk factors correlated with mental health, the
occurrence of anxiety and depression, and the health
outcomes of ART recipients all render this issue an
urgent research priority. However, previous research
d o e sn o t-i no n ea n dt h es a m es t u d y-s i m u l t a n e o u s l y
incorporate all correlates of anxiety and depression in
people receiving ART, despite the fact that such a com-
prehensive framework and knowledge is vital with a
view to developing appropriate interventions. This study
fills this particular research gap by simultaneously asses-
sing the impact of demographic, socio-economic, beha-
vioural, psychosocial, and health variables on symptoms
of anxiety and depression in a population of public sec-
tor ART patients in the Free State Province of South
Africa.
Methods
Data
This study is part of a cohort study entitled “Effective
Aids Treatment and Support in the Free State (FEATS)”
that was conducted by the Centre for Health Systems
Research and Development (CHSR&D) of the University
of the Free State (UFS). The study was approved by the
Ethics Committee of the Faculty of Health Sciences of
the UFS [ETOVS 145/07, DOH-27-0907-2025]. Study
participants were recruited in 2007/08 from twelve pub-
lic ART clinics in five districts in the Free State. Inclu-
sion criteria were being eighteen years or older, having
commenced ART in the five weeks prior to recruitment,
and, residing in the town or village where the particular
health facility was located. Data were collected by
trained enumerators using structured face-to-face inter-
views once written informed consent had been obtained
from study participants. The target sample size was 648
study participants and households. Because not all
households consented to participate in the study, addi-
tional patients were recruited, this resulting in a total of
716 study participants.
Measures
As specified in detail in the Appendix below, data on
demographic, socio-economic, behavioural, psychosocial
and health variables were collected. Socio-economic vari-
ables included: ‘education level’, ‘dwelling type ‘,’ finan-
cial statuses, and ‘food supplements’. Behavioural
variables comprised: ‘use of alcohol’, ‘use of tobacco’,
‘use of dagga’,a n d‘engagement in sexual activity’. Psy-
chosocial factors included: ‘stigma’, ‘coping’, and ‘psycho-
social support’. Psychosocial support included the
variables ‘treatment buddy’, ‘community worker’, ‘sup-
port group’ and ‘disclosure’ [29,30]. Health-related vari-
ables included ‘health-related quality of life’ (EQ-VAS)
[31,32], ‘time since first HIV + test’,a n d‘ART side
effects’.
In this study, anxiety and depression referred to self-
reported symptoms of anxiety and depression and not
Axis I anxiety and depressive clinical disorders. Symp-
toms of anxiety and depression were measured using
HADS, which was originally developed as a self-adminis-
tered tool to assess anxiety and depression in medically
ill patients [33]. The scale contains four response
options and comprises two subscales of seven questions
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respectively and range from 0-21, with a higher score
denoting a greater number of symptoms of either anxi-
ety or depression. Previous psychometric investigations
have shown that HADS achieves both good internal
consistency and test-retest reliabilities, is sensitive to
change, and provides valid assessments in HIV-positive
populations [34,35] in resource-limited settings [36,37].
For the purposes of this study, the instrument was
translated into SeSotho. The Cronbach’sa l p h a sf o rt h e
subscales were 0.66 for anxiety and 0.61 for depression
[38]. In this study, HADS scores were converted into a
binary categorical variable, with an 8 + score being used
to identify possible cases of clinical anxiety and depres-
sion [33,34]. A study in Brazil of HIV + women also
used a score of greater than 7 to identify symptoms of
anxiety or depression [36,37]. A review of the psycho-
metric properties of HADS moreover found that “[O]
ptimal balance between sensitivity and specificity for
HADS as a screening instrument was achieved most fre-
quently at a cut-off score of 8+ for both HADS-A[nxi-
ety] and HADS-D[epression]” [39].
Data analysis
STATA Version 11 was used to perform the statistical
data analysis. Firstly, descriptive statistics of the anxiety
and depression measures were generated with the aim
of assessing the prevalence of anxiety and depression in
the study population. Secondly, descriptive statistics of
sociodemographic and ART characteristics of study par-
ticipants were compiled. Finally, two sets of multivariate
logistic regression analyses were run, using anxiety and
depression as separate dependent variables to investigate
correlates of anxiety and depressive symptoms indepen-
dently. A literature review on HIV/AIDS, antiretroviral
treatment, and anxiety and depression informed the spe-
cification of the multivariatel o g i s t i cr e g r e s s i o nm o d e l s
[11,25,26,40,41]. The independent variables in the multi-
variate regression models were: residential district, gen-
der, age, marital status, education level, dwelling type,
treatment buddy, community worker, support group,
positive coping, avoidant coping, seeking-social-support
coping, stigma, disclosure, use of alcohol, use of
tobacco, use of dagga, sexual activity, financial status,
food supplements, time since first HIV test, ART side
effects and health-related quality of life (EQ-VAS).
Results
The majority of the study participants were black
(98.4%) and female (75.7%). The mean age of the study
participants was 37 years, and the median age was 36
years [IQR: 30.79-42.79]. Participants were mostly single
(41.5%), while 23.7% were living with a spouse or part-
ner, 14.6% were widowed and 10.6% were separated or
divorced. The majority of the study participants lived in
formal dwellings (66.6%) and 19.5% lived in informal
dwellings. Most study participants had some education,
mainly some secondary (45.8%) or primary education
(31.0%). All the study participants had commenced
ART, and the mean treatment duration was 37.7 days,
with a median of 30 days [IQR: 18.0-46.5]. The preva-
l e n c eo fs y m p t o m so fa n x i e t yw a s3 0 . 6 %a n dt h a tf o r
depression was 25.4%.
Correlates of anxiety
The multivariate logistic regression analysis identified the
following variables as correlates of symptoms of anxiety
in people receiving ART (Table 1). HIV + patients who
experienced very disruptive side effects from ART
reported more of the symptoms of anxiety than did
patients who had not reported side effects (OR = 3.62, CI
1.95-6.74). An avoidant coping style (OR = 1.42, CI 1.22-
1.65) and stigma (OR = 1.14, CI 1.07-1.21) were also
positively correlated with symptoms of anxiety. Finally,
the longer study participants had known their HIV status,
the more symptoms of anxiety they were likely to have
experienced (OR = 1.01, CI 1.00-1.02).
Correlates of depression
T h em u l t i v a r i a t el o g i s t i cr e g ression analysis identified
the following variables as correlates of depressive symp-
toms in people receiving ART (Table 2). Stigma was
positively correlated with symptoms of depression (OR
= 1.13, CI 1.06-1.20). The longer participants had
known their HIV + status, the more symptoms of
depression they were likely to have been experiencing
(OR = 1.02, CI 1.01-1.03). Respondents who participated
in a support group were less likely to have been
depressed than those who had not belonged to a sup-
port group (OR = 0.21, CI 0.05-0.99). Finally, widowed
study participants experienced fewer symptoms of
depression than those who were single (OR = 0.30, CI
0.13-0.69).
Discussion
This study represents one of a few studies that systema-
tically and simultaneously investigated correlates of
symptoms of anxiety and depression in patients enrolled
in a public sector ART programme in a resource-limited
setting. Two risk factors, namely severe side effects and
avoidant coping, were correlated with increased symp-
toms of anxiety, while a protective factor- participating
in a support group- was associated with a decrease in
symptoms of depression. Another risk factor, namely
stigma, was associated with an increase in symptoms of
both anxiety and depression.
Very disruptive ART side effects were correlated with
more of the symptoms of anxiety amongst our study
Pappin et al. BMC Public Health 2012, 12:244
http://www.biomedcentral.com/1471-2458/12/244
Page 3 of 9Table 1 Multivariate logistic regression analysis of factors correlated with symptoms of anxiety in HIV + respondents
on ARV treatment
Odds Ratio P-value 95% conf. Interval
District (comparison group = Lejweleputswa)
Motheo 1.29 0.59 - 2.80
Fezile Dabi 1.06 0.51 - 2.20
Thabo Mofutsanyane 0.89 0.47 - 1.71
Xhariep 3.98 0.83 - 19.16
Female 0.70 0.38 - 1.28
Age (comparison group = under 30)
30-34 years 0.79 0.35 - 1.80
35-39 years 0.52 0.23 - 1.16
40-44 years 1.13 0.50 - 2.54
45+ years 0.72 0.30 - 1.72
Marital status (comparison group = single)
Cohabiting 0.55 0.27 - 1.11
Not cohabiting 0.72 0.34 - 1.56
Widowed 0.65 0.30 - 1.41
Separated or divorced 0.76 0.31 - 1.85
Education (comparison group = none)
Primary 0.65 0.20 - 2.15
Some secondary 0.38 0.11 - 1.27
Matric and post-matric 0.49 0.14 - 1.78
Dwelling (comparison group = formal dwelling)
Informal 0.92 0.48 - 1.74
Traditional 0.69 0.27 - 1.72
Other 0.41 0.17 - 1.00
Treatment buddy (yes/no) 0.91 0.67 - 1.25
Community worker (yes/no) 0.79 0.29 - 2.19
Support group (yes/no) 0.79 0.20 - 3.18
Positive coping 0.88 0.55 - 1.41
Avoidant coping 1.42 ** 1.22 - 1.65
Seeking social-support coping 0.73 0.54 - 1.00
Stigma scale 1.14 ** 1.07 - 1.21
Disclosure (comparison group = none)
Disclosed to some 2.97 0.56 - 15.83
Disclosed to all 4.33 0.92 - 20.37
Drink alcohol (yes/no) 0.69 0.30 - 1.55
Smoke tobacco (yes/no) 1.05 0.42 - 2.63
Smoke dagga (yes/no) 0.43 0.10 - 1.94
Sexual activity (comparison group = no sex)
Always use a condom 1.52 0.91 - 2.54
Inconsistent condom use 1.51 0.58 - 3.93
Never use a condom 0.99 0.18 - 5.36
Financial status (comparison group = disability grant)
Old-age pension 1.63 0.48 - 5.53
Child grant 2.12 0.45 - 9.92
Employed 0.75 0.37 - 1.52
Support within the household 0.64 0.32 - 1.27
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Free State found that adverse side effects of treatment
negatively affected the emotional well-being of the
patients. The authors thus recommended that health
care workers be vigilant regarding possible adverse side
effects of treatment [42].
Our study did not find an association between coping
strategies and depression [13,25,26,43]. However, unlike
previous research, this study did investigate the associa-
tion between coping strategies and anxiety. In this
study, avoidant coping was correlated with a greater
number of the symptoms of anxiety. It has been sug-
gested that coping strategies of patients should be iden-
tified, and that patients using maladaptive strategies
should receive therapeutic counseling [25].
Participating in a support group was associated with
fewer symptoms of depression. This finding is in agree-
ment with a study conducted in Thailand where low
levels of social support were associated with increased
levels of depression [19]. Social support is a protective
coping mechanism that may assist HIV + people in sol-
ving problems and in expressing emotions, thereby
reducing psychological distress [44-46].
In this study, perceived stigma was associated with
symptoms both of anxiety and depression. This outcome
confirms the findings from the literature that stigma is
an important risk factor associated with depression
[17,18,21,41]. The finding that stigma is associated with
anxiety adds new evidence to the literature on the debil-
itating role that stigma may play in the lives of people
receiving ART.
Whereas it is well established that widows and
widowers face a greater risk of depression, especially in
the immediate aftermath of bereavement [47], this study
found widowhood to offer protection against symptoms
of depression, which may be attributed to access to both
material support and especially psychosocial support
within their extended family and kinship networks
[48-50].
The study has the following limitations; firstly, study
participants were drawn only from those HIV + indivi-
duals who had gained access to the public sector antire-
troviral treatment programme and had successfully
completed drug-readiness training. Patients suffering
from anxiety and depression may be less likely to seek
care, complete drug readiness, and initiate treatment.
They are thus under-represented in this study. Secondly,
because the empirical analysis was based on self-
reported information, the measures may not be comple-
tely accurate. Particularly problematic variables include
self-reported side effects and sexual behaviour. Thirdly,
this was a cross-sectional study, so that all the data were
measured at the same time. Consequently, causality
between symptoms of anxiety and depression and their
correlates could not be firmly established. Fourthly,
although according to some authors “the HADS appears
to represent the best currently available self-report to
reliably and validly assess anxiety and depression in HIV
infected patients” [34], it has not yet been validated
among HIV + patients initiating ART in South Africa.
In the fifth instance, the Cronbach’s alpha for the two
subscales is below the threshold of 0.70. The scale may
Table 1 Multivariate logistic regression analysis of factors correlated with symptoms of anxiety in HIV + respondents
on ARV treatment (Continued)
Support outside the household 0.74 0.30 - 1.83
Other 1.30 0.57 - 2.95
Food supplements (comparison group = never)
Previously 0.41 0.15 - 1.17
Currently 0.36 0.12 - 1.06
Time since first HIV + test 1.01 * 1.00 - 1.02
Side effects (comparison group = no side effects)
Somewhat disruptive side effects 1.76 0.94 - 3.31
Very disruptive side effects 3.62 ** 1.95 - 6.74
Health-related quality of life (EQ-VAS) 0.99 0.98 - 1.01
Sample size 499
Wald-statistic 106.8
P-value < 0.001
R2 0.22
% successfully predicted 78.56
Note: *p-value ≤ 0.05
**p-value ≤ 0.01
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respondents on ARV treatment
Odds Ratio P-value 95% conf. Interval
District (comparison group = Lejweleputswa)
Motheo 0.91 0.42 - 1.98
Fezile Dabi 0.84 0.37 - 1.89
Thabo Mofutsanyane 1.08 0.54 - 2.14
Xhariep 0.41 0.04 - 3.90
Female 0.93 0.50 - 1.72
Age (comparison group = under 30)
30-34 years 1.21 0.54 - 2.70
35-39 years 1.72 0.76 - 3.87
40-44 years 1.68 0.73 - 3.89
45+ years 2.30 0.93 - 5.67
Marital status (comparison group = single)
Cohabiting 0.75 0.38 - 1.48
Not cohabiting 0.64 0.26 - 1.59
Widowed 0.30 * 0.13 - 0.69
Separated or divorced 0.89 0.40 - 1.99
Education (comparison group = none)
Primary 1.87 0.44 - 7.99
Some secondary 1.24 0.29 - 5.34
Matric and post-matric 1.11 0.23 - 5.30
Dwelling (comparison group = formal dwelling)
Informal 0.82 0.39 - 1.74
Traditional 1.11 0.48 - 2.55
Other 0.92 0.39 - 2.15
Treatment buddy (yes/no) 1.20 0.88 - 1.64
Community worker (yes/no) 0.91 0.30 - 2.71
Support group (yes/no) 0.21 * 0.05 - 0.99
Positive coping 0.68 0.44 - 1.06
Avoidant coping 1.01 0.98 - 1.04
Seeking social-support group 1.05 0.75 - 1.49
Stigma scale 1.13 ** 1.06 - 1.20
Disclosure (comparison group = none)
Disclosed to some 0.43 0.09 - 2.08
Disclosed to all 1.18 0.29 - 4.90
Drink alcohol (yes/no) 0.83 0.38 - 1.79
Smoke tobacco (yes/no) 1.61 0.66 - 3.93
Smoke dagga (yes/no) 0.39 0.10 - 1.50
Sexual activity (comparison group = no sex)
Always use a condom 0.90 0.53 - 1.51
Inconsistent condom use 1.12 0.45 - 2.77
Never use a condom 0.93 0.20 - 4.35
Financial status (comparison group = disability grant)
Old-age pension 0.64 0.19 - 2.14
Child grant 1.47 0.31 - 7.01
Employed 0.74 0.37 - 1.49
Support within the household 0.73 0.36 - 1.49
Pappin et al. BMC Public Health 2012, 12:244
http://www.biomedcentral.com/1471-2458/12/244
Page 6 of 9thus not be all that reliable [38]. For the purposes of
this study, the instrument was translated into SeSotho.
Further research is consequently required so as to
ensure the reliability and validity of the translated ver-
sion. Finally, by using a low cut-off of 8+ the study may
be missing important correlates of mild (8-10), moderate
(11-15) and particularly severe (16-21) symptoms of
anxiety and depression [51]. The small number of severe
cases observed in this study [anxiety n = 7, depression n
= 4] precluded meaningful statistical analysis. In larger
samples, multivariate multinomial logistic regression
o f f e r sam e t h o db yw h i c hj o i n t l yt od e t e r m i n ef a c t o r s
correlated with each of the four classes of symptoms of
anxiety and depression.
Conclusions
This study sheds some light on the nature of symptoms
of anxiety and depression in patients receiving ART in a
resource-limited setting. The prevalence of symptoms of
anxiety was 30.6% and that of depression was 25.4%.
Severe side effects of ART, avoidant coping strategies,
participating in a support group and stigma are corre-
lates of anxiety and/or depression.
This study has both theoretical and practical
implications.
From a theoretical point of view, the impact of ART
side effects, coping strategies, support groups and stig-
matisation on the mental health of HIV/AIDS patients
draws attention to the inter-linked nature of treatment
aspects, social support and mental health in achieving
durable ART success. However, further research is
required so as fully to disentangle the complex
interrelationships between these social, mental and phy-
sical aspects of public-sector ART in high HIV-preva-
lence resource-limited settings.
From the perspectives of practical policy and manage-
ment, the study findings provide valuable insights into
psychosocial aspects of the Free State public-sector ART
programme. Combined with the literature on the intri-
cate link between mental health problems and treatment
outcomes our results emphasise firstly, the necessity
that resources be allocated for screening and treating
mental-health problems, and, secondly, that interven-
tions are required that will encourage support-group
participation, address ART side effects, reduce maladap-
tive coping styles and minimise stigma associated with
symptoms of anxiety and/or depression.
Appendix: Details of measures
Data on demographic, socio-economic, behavioural, psy-
chosocial and health variables were collected. Demo-
graphic variables included ‘district of residence’,
‘gender’, ‘age’ and ‘marital status’.T h ev a r i a b l emarital
status comprised ‘single’, ‘cohabiting’, ‘not-cohabiting’,
‘widowed’,a n d‘separated or divorced’. ‘Single’ refers to
participants without any type of partner, ‘cohabiting’
refers to participants who lived with a partner irrespec-
tive of whether or not they were married, and ‘not-coha-
biting’ refers to participants whose partners (married or
not) lived elsewhere at the time of the interview.
Socio-economic variables included ‘education level’,
‘dwelling type’, ‘financial status’, and ‘food supplements’.
Education level comprised four categories: ‘none’, ‘pri-
mary’, ‘some secondary’, ‘matric’ (Grade 12) and ‘post-
Table 2 Multivariate logistic regression analysis of factors correlated with symptoms of depression in HIV + respon-
dents on ARV treatment (Continued)
Support outside the household 1.11 0.44 - 2.78
Other 0.68 0.26 - 1.78
Food supplements (comparison group = never)
Previously 0.56 0.18 - 1.76
Currently 0.32 0.10 - 1.00
Time since first HIV + test 1.02 ** 1.01 - 1.03
Side effects (comparison group = no side effects)
Somewhat disruptive side effects 1.05 0.54 - 2.05
Very disruptive side effects 1.79 0.92 - 3.46
Health-related quality of life (EQ-VAS) 0.99 0.97 - 1.00
Sample size 499
Wald-statistic 82.26
P-value < 0.001
R2 0.17
% successfully predicted 78.96
Note: *p-value ≤ 0.05
**p-value ≤ 0.01
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mal’, ‘informal’, ‘traditional’,a n d ,‘other’. Other included
‘a flat or apartment in a block of flats’, ‘a dwelling in a
backyard’ and ‘ah o s t e l ’. Financial status refers to how
participants usually support themselves. The seven cate-
gories were: ‘disability grant’, ‘old-age pension’, ‘child-
support grant’, ‘employed’, ‘support within the house-
hold’, ‘support outside the household’,a n d , ’other’.T h e
variable food supplements referred to the respondents’
having received food supplements as part of the govern-
ment’s ARV treatment programme. The categories were
‘never’, ‘previously’ or ‘currently’.
Behavioural variables included ‘use of alcohol’, ‘use of
tobacco’, ‘use of dagga’, and ‘engagement in sexual activ-
ity’. ‘Use of alcohol’, ‘use of tobacco’,a n d‘use of dagga’
were dichotomous variables, referring only to whether
or not a person engaged in the activity rather than
establishing the extent to which the person was doing
so. Sexual activity r e f e r r e dt ow h e t h e ro rn o tp a r t i c i -
pants had had sexual intercourse in the six months
prior to the study, and if so, whether they had used a
condom. The four categories for this variable were: ‘no
sex’, ‘always used condom’, ‘inconsistent condom use’
and ‘never used a condom’.
Psychosocial factors included ‘stigma’, ‘coping’,a n d
‘psychosocial support’.T h estigma scale was generated
from eight items in the questionnaire, asking respon-
dents about the extent to which they agreed or dis-
agreed with perceptions that they or others had
regarding HIV and AIDS. The possible responses were:
‘strongly disagree’, ‘disagree’, ‘agree’ or ‘strongly agree’
[52]. The scale reported an alpha of 0.70 [31]. Three
coping behaviours were measured: ‘positive’, ‘avoidant’
and ‘seeking social support coping styles’.R e s p o n d e n t s
were asked to describe how they were currently (at the
time of the study) dealing with living with HIV and
AIDS by answering ‘yes’ or ‘no’ to sixteen statements.
The statements were taken from a study conducted in
the United States between 1988 and 1989. In that study,
a factor analysis of the sixteen coping behaviours of
1031 people with AIDS revealed ‘positive’, ‘avoidant’ and
‘seeking social support’ to be three main coping
mechanisms of people with AIDS [26]. Psychosocial sup-
port included four questions concerning ‘a treatment
buddy’, ‘community worker’, ‘support group’ and ‘disclo-
sure’, the first three of which were dichotomous vari-
ables. ‘Treatment buddy’ refers to whether the
respondent at the time of the present study had a treat-
ment buddy; ‘community worker’ denotes whether the
participant at the time had a community worker visiting
the participant at home; and ‘support group’ refers to
whether the participant at the time of the study
belonged to a support group. ‘Disclosure’ refers to the
extent to which participants had disclosed to the three
most important people in their lives, with response cate-
gories of ‘none’, ‘some’ and ‘all’.
Health variables included ‘health-related quality of life’
(EQ-VAS), ‘time since first HIV + test’, and ‘side effects’.
‘EQ-VAS’ is a visual analogue scale that measures a par-
ticipant’s health “today” and ranges from 0% (worst
health) to 100% (best health). ‘Time since first HIV +
test’ refers to the number of months the study partici-
pant had known their HIV + status. ‘Side effects’ refer
to whether the participant experienced side effects from
ART, and, if so, how disruptive these side effects were:
‘no side effects’, ‘somewhat disruptive’ or ‘very
disruptive’.
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